Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
RVMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$29.17 - $62.40
Previous CloseN/A
Volume180.68K
Average Volume (3M)1.92M
Market Cap
$6.97B
Enterprise Value$6.10B
Total Cash (Recent Filing)$543.06M
Total Debt (Recent Filing)$135.84M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Aug 06, 2025EPS Estimate
-1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding186,261,750
10 Day Avg. Volume1,893,053
30 Day Avg. Volume1,915,587
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.94
Forecast
1Y Price Target
$70.60Price Target Upside68.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Revolution Medicines News
---
Bulls Say, Bears Say
Bulls Say
Clinical DataThe efficacy data were highlighted by a 61% overall response rate among patients who received zoldonrasib.
Earnings And StrategyThe strategy in 1L NSCLC along with new data shared at the earnings is expected to have a positive impact on RVMD stock.
Market PotentialEncouraging clinical data from the innovative RAS(ON) platform, coupled with the large addressable population of RAS-dependent cancers, support a positive long-term outlook for RVMD.
Bears Say
Competitive LandscapeThe zoldonrasib NSCLC data reinforces RVMD's leading position within the increasingly competitive RAS inhibitor landscape.
Treatment ChallengesThere were slightly higher percentages of dose interruptions and one patient discontinued treatment, reflecting minor challenges in treatment continuation.
---
Ownership Overview
6.44% Insiders
25.80% Mutual Funds
0.05% Other Institutional Investors
51.81% Public Companies and
Individual Investors
RVMD FAQ
What was Revolution Medicines’s price range in the past 12 months?
Revolution Medicines lowest stock price was $29.17 and its highest was $62.40 in the past 12 months.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market cap is $6.97B.
When is Revolution Medicines’s upcoming earnings report date?
Revolution Medicines’s upcoming earnings report date is Aug 06, 2025 which is in 88 days.
How were Revolution Medicines’s earnings last quarter?
Revolution Medicines released its earnings results on May 07, 2025. The company reported -$1.13 earnings per share for the quarter, missing the consensus estimate of -$1.097 by -$0.033.
Is Revolution Medicines overvalued?
According to Wall Street analysts Revolution Medicines’s price is currently Undervalued.
Does Revolution Medicines pay dividends?
Revolution Medicines does not currently pay dividends.
What is Revolution Medicines’s EPS estimate?
Revolution Medicines’s EPS estimate is -1.15.
How many shares outstanding does Revolution Medicines have?
Revolution Medicines has 186,261,750 shares outstanding.
What happened to Revolution Medicines’s price movement after its last earnings report?
Revolution Medicines reported an EPS of -$1.13 in its last earnings report, missing expectations of -$1.097. Following the earnings report the stock price went up 11.285%.
Which hedge fund is a major shareholder of Revolution Medicines?
Currently, no hedge funds are holding shares in RVMD
---
Revolution Medicines Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$70.60 (68.46% Upside)
$70.60 (68.46% Upside)
Blogger Sentiment
Neutral
RVMD Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 3.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $60.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 5.7%
Last 30 Days ▼ 5.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.12%
12-Months-Change
Fundamentals
Return on Equity
-36.68%
Trailing 12-Months
Asset Growth
24.65%
Trailing 12-Months
Company Description
Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
---
RVMD Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call provided an optimistic outlook with significant clinical advancements and a strong financial position, despite increased R&D expenses and net loss.Read More>---
RVMD Stock 12 Month Forecast
Average Price Target
$70.60
▲(68.46% Upside)
Technical Analysis
Teleflex
―
The Ensign Group
―
Blueprint Medicines
―
BridgeBio Pharma
―
Roivant Sciences
―
---